Journal of hepatology
-
Journal of hepatology · Jun 2011
Comment Letter Randomized Controlled TrialPropofol in patients with cirrhosis and minimal hepatic encephalopathy.
-
Journal of hepatology · Mar 2011
Symptomatic-enlarging hepatic hemangiomas are effectively treated by percutaneous ultrasonography-guided radiofrequency ablation.
We aimed to evaluate the feasibility, efficacy, and safety of percutaneous ultrasonography-guided radiofrequency ablation for the management of symptomatic-enlarging hepatic hemangiomas. ⋯ Percutaneous ultrasonography-guided radiofrequency ablation is an effective, minimally invasive, and safe procedure for the management of symptomatic-enlarging hepatic hemangioma.
-
Journal of hepatology · Feb 2011
Assessment of adrenocortical reserve in stable patients with cirrhosis.
Adrenal insufficiency (AI) is reported in critically ill patients with cirrhosis and is associated with increased mortality. It is unclear if AI is an underlying condition or triggered by critical events (e.g. sepsis). We investigated AI in cirrhosis without infection or hemodynamic instability. ⋯ AI defined by an abnormal response to 1 μg tetracosactrin is frequent in stable patients with cirrhosis, in the absence of infections or hemodynamic instability and is related to the severity of liver disease. However, evaluation of the true incidence of AI should comprise direct assays of free cortisol. Clinical consequences of AI need to be explored.
-
Journal of hepatology · Jan 2011
Randomized Controlled TrialSub-clinical hepatic encephalopathy in cirrhotic patients is not aggravated by sedation with propofol compared to midazolam: a randomized controlled study.
The risk of exacerbating sub-clinical hepatic encephalopathy (HE) by propofol has not been established. The aim of this study is to determine whether the use of propofol, for upper endoscopy in patients with cirrhosis, precipitates sub-clinical HE. ⋯ Sedation with propofol has a shorter time recovery and a shorter time to discharge than midazolam and does not exacerbate sub-clinical hepatic encephalopathy in patients with compensated liver cirrhosis.
-
Journal of hepatology · Jan 2011
Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis.
Data on the management of portal vein thrombosis (PVT) in patients with decompensated cirrhosis are extremely limited, particularly in the cases of the transjugular intrahepatic portosystemic shunt (TIPS). We assessed the outcome of TIPS for PVT in patients with cirrhosis and symptomatic portal hypertension and determined the predictors of technical success and survival. ⋯ TIPS should be considered a safe and feasible alternative therapy for chronic PVT in selected patients with decompensated cirrhosis. Both technical success and survival were closely associated with the degree of MPV occlusion.